Core Insights - The State Street Health Care Select Sector SPDR ETF (XLV) is a passively managed ETF launched on December 16, 1998, providing broad exposure to the Healthcare - Broad segment of the equity market [1] - XLV is the largest ETF in its category, with assets exceeding $40.99 billion, and aims to match the performance of the Health Care Select Sector Index [3] Fund Details - The ETF has an annual operating expense ratio of 0.08%, making it the least expensive option in the healthcare ETF space, with a 12-month trailing dividend yield of 1.56% [5] - The fund is fully allocated to the healthcare sector, with top holdings including Eli Lilly + Co (12.97%), Johnson + Johnson, and Abbvie Inc, which together account for approximately 57.14% of total assets [6][7] Performance Metrics - As of December 16, 2025, XLV has returned approximately 14.79% year-to-date and 12.45% over the past year, with a trading range between $128.77 and $158.77 in the last 52 weeks [8] - The ETF has a beta of 0.61 and a standard deviation of 13.38% over the trailing three-year period, indicating a medium risk profile [8] Alternatives - Other healthcare ETFs include iShares Global Healthcare ETF (IXJ) with $4.52 billion in assets and Vanguard Health Care ETF (VHT) with $17.53 billion, each with different expense ratios [11]

In the current market session, Insulet Inc. (NASDAQ:PODD) share price is at $296.82, after a 0.55% spike. Moreover, over the past month, the stock fell by 11.16%, but in the past year, went up by 9.73%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. Insulet P/E Compared to CompetitorsThe P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's c ...

In the current market session, Boston Scientific Inc. (NYSE:BSX) share price is at $94.18, after a 0.36% increase. Moreover, over the past month, the stock decreased by 9.36%, but in the past year, increased by 2.59%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. Boston Scientific P/E Ratio Analysis in Relation to Industry PeersThe P/E ratio measures the current share price to the company's EPS. It is used by ...

Looking into the current session, Koninklijke Philips Inc. (NYSE:PHG) shares are trading at $26.49, after a 5.53% decrease. Over the past month, the stock fell by 6.20%, but over the past year, it actually spiked by 1.07%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. Koninklijke Philips P/E Compared to CompetitorsThe P/E ratio measures the current share price to the company' ...

Core Viewpoint - IDEXX Laboratories Inc. has shown significant stock performance, with a 20.86% increase over the past month and an 81.78% increase over the past year, leading to discussions about its valuation based on the price-to-earnings (P/E) ratio [1][3]. Group 1: Stock Performance - The current stock price of IDEXX Laboratories Inc. is $766.68, reflecting a 1.93% increase in the current session [1]. - Long-term shareholders are optimistic about the company's performance due to substantial stock price increases [1]. Group 2: P/E Ratio Analysis - The P/E ratio is a critical metric for evaluating the company's market performance, comparing the current share price to its earnings per share (EPS) [3]. - IDEXX Laboratories Inc. has a P/E ratio of 59.65, which is higher than the industry average of 48.46 in the Health Care Equipment & Supplies sector, suggesting that investors may expect better performance from IDEXX compared to its peers [4]. - A higher P/E ratio may indicate that the stock is overvalued, but it could also reflect investor confidence in future growth and potential dividend increases [3][4]. Group 3: Limitations of P/E Ratio - While the P/E ratio is a useful tool for market performance analysis, it has limitations and should not be used in isolation [7][8]. - A lower P/E ratio might suggest undervaluation, but it could also indicate a lack of expected future growth [8]. - Other factors, such as industry trends and business cycles, should be considered alongside the P/E ratio for informed investment decisions [8].

Group 1 - The P/E ratio is a tool for long-term shareholders to evaluate a company's market performance against historical earnings and industry data [4] - Stryker Inc. has a P/E ratio of 48.97, which is higher than the industry average of 45.38, suggesting that shareholders may expect better performance from Stryker compared to its peers [5] - A higher P/E ratio could indicate that the stock is overvalued, despite potential expectations for superior performance [5] Group 2 - The P/E ratio should be used cautiously as it can indicate undervaluation or suggest weak growth prospects [7] - Investors should consider the P/E ratio alongside other financial metrics, industry trends, and qualitative factors for a comprehensive analysis [7] - A thorough evaluation of a company's financial health can lead to more informed investment decisions [7]

Core Viewpoint - Stryker Inc. has shown mixed short-term performance with a 0.27% drop in share price to $374.29, a 3.73% decline over the past month, but a 5.26% increase over the past year, prompting long-term shareholders to consider the company's price-to-earnings (P/E) ratio [1]. Group 1: Company Performance - Stryker Inc. shares are currently trading at $374.29, reflecting a 0.27% decrease [1]. - The stock has experienced a 3.73% decline over the past month, while it has increased by 5.26% over the past year [1]. Group 2: P/E Ratio Analysis - The P/E ratio is a critical metric for long-term shareholders to evaluate the company's market performance against historical earnings and industry standards [5]. - Stryker Inc. has a P/E ratio of 49.71, which is higher than the industry average of 46.24 in the Health Care Equipment & Supplies sector [6]. - A higher P/E ratio may suggest that shareholders expect Stryker Inc. to outperform its industry, but it could also indicate that the stock is overvalued [6].

Core Viewpoint - Intuitive Surgical Inc. has shown mixed performance, with a slight increase in the short term but a significant decline over the past year, prompting long-term shareholders to reassess the company's price-to-earnings (P/E) ratio [1]. Group 1: Stock Performance - The current share price of Intuitive Surgical Inc. is $446.32, reflecting a 0.20% drop in the current market session [1]. - Over the past month, the stock has increased by 0.11%, while it has decreased by 7.92% over the past year [1]. Group 2: P/E Ratio Analysis - The P/E ratio is a critical metric for long-term shareholders to evaluate the company's market performance against historical earnings and industry standards [5]. - Intuitive Surgical has a P/E ratio of 62.38, which is higher than the industry average P/E ratio of 44.86 for the Health Care Equipment & Supplies sector [6]. - A higher P/E ratio may suggest that the stock is overvalued, despite the potential for better future performance compared to its industry peers [6]. Group 3: Investment Considerations - While the P/E ratio is a useful tool for assessing market performance, it should be interpreted cautiously, as a low P/E can indicate undervaluation or weak growth prospects [10]. - Investors should consider the P/E ratio alongside other financial metrics, industry trends, and qualitative factors for a comprehensive analysis of the company's financial health [10].

Core Viewpoint - Insulet Inc. (NASDAQ:PODD) has experienced a short-term decline in stock price while showing significant long-term growth, prompting a review of its price-to-earnings (P/E) ratio by long-term shareholders [1]. Group 1: Stock Performance - Insulet Inc. shares are currently trading at $306.78, reflecting a 1.24% drop in the current session [1]. - The stock has decreased by 11.06% over the past month but has increased by 31.87% over the past year [1]. Group 2: P/E Ratio Analysis - The P/E ratio is a critical metric for long-term shareholders to evaluate the company's market performance relative to historical earnings and industry standards [5]. - Insulet Inc. has a P/E ratio of 94.7, which is significantly higher than the aggregate P/E ratio of 42.89 in the Health Care Equipment & Supplies industry [6]. - A higher P/E ratio may suggest that shareholders expect Insulet Inc. to outperform its industry or that the stock is potentially overvalued [6]. Group 3: Limitations of P/E Ratio - While the P/E ratio is useful for market performance analysis, it has limitations and should not be used in isolation [9]. - A lower P/E may indicate undervaluation or a lack of expected future growth, emphasizing the need for a comprehensive analysis that includes other financial metrics and qualitative factors [9].

Core Insights - The Health Care Select Sector SPDR ETF (XLV) is designed to provide broad exposure to the Healthcare - Broad segment of the equity market, launched on December 16, 1998 [1] - XLV is the largest ETF in the Healthcare - Broad segment, with assets exceeding $32.7 billion [3] - The ETF has a low annual operating expense of 0.08% and a 12-month trailing dividend yield of 1.8% [5] Index and Holdings - The Health Care Select Sector Index includes companies from various industries such as pharmaceuticals, health care providers & services, health care equipment & supplies, biotechnology, life sciences tools & services, and health care technology [4] - Eli Lilly + Co (LLY) is the largest holding, accounting for approximately 12.82% of total assets, with the top 10 holdings representing about 55.33% of total assets [7][6] Performance Metrics - As of August 14, 2025, XLV has experienced a loss of about 2.24% year-to-date and a decline of approximately 10.27% over the past year [8] - The ETF has traded between $128.77 and $157.24 in the last 52 weeks, with a beta of 0.62 and a standard deviation of 14.03% over the trailing three-year period, indicating medium risk [8] Alternatives and Rankings - XLV holds a Zacks ETF Rank of 1 (Strong Buy), indicating strong expected returns based on various factors [9] - Other ETFs in the healthcare space include iShares Global Healthcare ETF (IXJ) with $3.72 billion in assets and Vanguard Health Care ETF (VHT) with $15.11 billion in assets, with expense ratios of 0.41% and 0.09% respectively [10]